Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 7/20 | 0.55 |
| ▸ | RAF1 | P04049 | 9/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 13/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 11/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 11/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 11/20 | 0.55 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.55 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.53 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.51 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.51 |
| ▸ | GCGR | P47871 | 3/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12461959 | 0.91 | RAF1 (0.57) | BRAFRAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL12461191 | 0.89 | RAF1 (0.60) | BRAFRAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL12461172 | 0.86 | ALOX5 (0.64) | BRAFRAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL12461160 | 0.85 | RAF1 (0.62) | BRAFRAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL2148151 | 0.83 | MAPK14 (0.68) | BRAFRAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL12461960 | 0.82 | RAF1 (0.62) | BRAFRAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL2148438 | 0.81 | RAF1 (0.58) | BRAFRAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL12461958 | 0.81 | MAPK14 (0.65) | BRAFRAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL12461957 | 0.78 | MAPK14 (0.60) | BRAFRAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL2949385 | 0.74 | MAPK13 (1.00) | BRAFRAF1MAPK14MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040983-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION | 2013-02-14 | — | — | US | disclosed |
| US-20130040983-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION | 2013-02-14 | — | — | US | disclosed |
| WO-2011085269-A1 | RAF KINASE INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040983-A1 | RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | BRAF 1/4885RAF1 2/4885MAPK14 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.